Dermata Therapeutics (DRMAW) Stock Price, News & Analysis

Company Overview

Dermata Therapeutics is a clinical-stage biopharmaceutical company focused on developing targeted therapies for inflammatory skin diseases. The company leverages small-molecule approaches to modulate key immune and cellular pathways in dermatologic conditions that currently lack effective or safe long-term treatments. Headquartered in Cambridge, Massachusetts, Dermata is advancing novel programs designed to address both common and severe skin disorders.

The company’s lead pipeline includes a selective topical PI3Kδ inhibitor being evaluated for the treatment of atopic dermatitis, where dysregulated immune signaling drives chronic inflammation and barrier dysfunction. In parallel, Dermata is developing Rho kinase inhibitors aimed at conditions such as hidradenitis suppurativa and other inflammatory lesions. These clinical-stage candidates have been engineered for localized delivery to minimize systemic exposure while maximizing therapeutic impact in affected skin areas.

Dermata’s management team brings together experienced professionals in immunology, dermatology and pharmaceutical development. By combining proprietary chemistry platforms with insights into skin biology, the company aims to advance its product candidates through proof-of-concept trials and into later-stage development. Dermata continues to collaborate with academic partners and contract research organizations to support ongoing clinical studies and to expand its pipeline into additional indications with high unmet medical need.

Key Stats

• Today's Range: $0.02 to $0.03
• 50-Day Range: $0.02 to $0.02
• 52-Week Range: $0.01 to $0.04
• Volume: 19,148 shs
• Average Volume: 10,402 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DRMAW Stock Analysis - Frequently Asked Questions

How have DRMAW shares performed this year?

Dermata Therapeutics' stock was trading at $0.0107 at the beginning of the year. Since then, DRMAW stock has increased by 51.4% and is now trading at $0.0162.

How do I buy shares of Dermata Therapeutics?

Shares of DRMAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:DRMAW
• CIK: 1853816
• Web: www.dermatarx.com
• Phone: 858-800-2543
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A